Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 6, 2013, Pages 334-350

  Palumbo, Raffaella ^a   Sottotetti, Federico ^a   Teragni, Cristina ^a   Pozzi, Emma ^a   Quaquarini, Erica ^a   Tagliaferri, Barbara ^a   Bernardo, Antonio ^a   Riccardi, Alberto ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

chemotherapy; HER2 targeted therapies; metastatic breast cancer; subsequent lines; survival benefit

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

EID: 84896923380     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834013508197     Document Type: Article

References (81)

1. Andre F. Slimane K. Bachelot T. Dunant A. Namer M. Barrelier A. et al. (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period, J Clin Oncol 22: 3302–3308.
2. Banerji U. Kuciejewska A. Ashley S. Walsh G. O'Brien M. Johnston S. et al. (2007) Factors determining outcome after third line chemotherapy for metastatic breast cancer. Breast 16: 359–366.
3. Barrios C. Liu M. Lee S. Vanlemmens L. Ferrero J. Tabei T. et al. (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121: 121–131.
4. Bartsch R. Wenzel C. Hussian D. Pluschnig U. Sevelda U. Koestler W. et al. (2006) Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6: 63.
5. Baselga J. Gelmon K.A. Verma S. Wardley A. Conte P. Miles D. et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–1144.
6. Bernardo G. Palumbo R. Poggi G. Bernardo A. Teragni C. Frascaroli M. et al. (2010) Beyond the second line chemotherapy in metastatic breast cancer: when stop the treatment between science and conscience. Cancer Res 70(24 Suppl.): 446s, P6-11-03.
7. Blackwell K. Burstein H. Storniolo A. Rugo H. Sledge G. Aktan G. et al. (2012) Overall survival benefit with Lapatinib in combination with Trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF 104900 Study. J Clin Oncol 30: 2585–2592.
8. Bonneterre J. Roché H. Monnier A. Guastalla J.P. Namer M. Fargeot P. et al. (2002) Docetaxel versus 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210–1215.
9. Bontenbal M. Andersson M. Wildiers J. Cocconi G. Jassem J. Paridaens R. et al. (1998) Doxorubicin versus epirubicin, report of a second-line randomized phase II / III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer 77: 2257–2263.
10. Brufsky A. Hurvitz S. Perez E. Swamy R. Valero V. O'Neill V. et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29: 4286–4293.
11. Burzykowski T. Buyse M. Piccart-Gebhart M. Sledge G. Carmichael J. Luck H. et al. (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26: 1987–1992.
12. Campiglio M. Bufalino R. Sandri M. Ferri E. Aiello R. de Matteis A. et al. (2011) Increased overall survival independent of RECIST response in metastatic breast cancer patient continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 128: 147–154.
13. Cancello G. Montagna E. D'Agostino D. Giuliano M. Giordano A. Plaitano M. et al. (2008) Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 10: R60.
14. Cardoso F. Costa A. Norton L. Cameron D. Cufer T. Fallowfield L. et al. (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21: 242–252.
15. Cardoso F. Di Leo A. Lohrisch C. Bernard C. Ferreira F. Piccart M. (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197–207.
16. Cardoso F. Fallowfield L. Costa A. Castiglione and Senkus E. on behalf of the ESMO Guidelines Working Group (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl. 6): vi25–vi30.
17. Chan S. Friedrichs K. Noel D. Pintér T. van Belle S. Vorobiof D. et al. (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354.
18. Chia S. Speers C. D'Yachkova Y. Kang A. Malfair-Taylor S. Barnett J. et al. (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110: 973–979.
19. Chung C. Carlson R. (2003) Goals and objectives in the management of metastatic breast cancer. Oncologist 8: 514–520.
20. Corey-Lisle P. Peck R. Mukhopadhyay P. Orsini L. Safikhani S. Bell J. (2012) Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer 118: 461–468.
21. Cortes J. O'Shaughnessy J. Loesch D. Blum J. Vahdat L. Petrakova K. et al. (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase III open-label randomized study. Lancet 377: 914–923.
22. Dawood S. Broglio K. Buzdar A.U. Hortobagyi G. Giordano S. (2010) Prognosis of women with metastatic breast cancer by HER 2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28: 92–98.
23. Dawood S. Broglio K. Gonzalez-Angulo A. Buzdar A. Hortobagyi G. Giordano S. (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26: 4891–4898.
24. Dufresne A. Pivot X. Tournigand C. Facchini T. Altweegg T. Chaigneau L. (2008) Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107: 275–279.
25. Esposito A. Munzone E. Bagnardi V. Adamoli L. Sciandivasci A. Cullurà D. et al. (2012) Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients? Anticancer Drugs 23: 1089–1098.
26. Extra J. Antoine E. Vincent-Salomon A. Delozier T. Kerbrat P. Bethune-Volters A. et al. (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15: 799–809.
27. Fabi A. Metro G. Ferretti G. Giannarelli D. Papaldo P. Mottolese M. et al. (2008) Do HER2-positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A monoinstitutional experience and systematic review of observational studies. Breast 17: 499–505.
28. Fountzilas G. Razis E. Tsavdaridis D. Karina M. Labropoulos S. Christodoulou C. et al. (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Clin Breast Cancer 4: 120–125.
29. Fossati R. Confalonieri C. Torri V. Ghislandi E. Penna A. Pistotti V. et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460.
30. García-Sáenz J. Martín M. Puente J. López-Tarruella S. Casado A. Moreno F. et al. (2005) Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 6: 325–329.
31. Gelmon K. Mackey J. Verma S. Gertler S. Bangemann N. Klimo P. et al. (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5: 52–58.
32. Gennari A. Conte P. Rosso R. Orlandini C. Bruzzi P. (2005) Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 15: 1742–1750.
33. Gennari A. Stockler M. Puntoni M. Sormani M. Nanni O. Amadori D. et al. (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29: 2144–2149.
34. Geyer C. Forster J. Lindquist D. Chan S. Romieu C. Pienkowski T. et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743.
35. Giordano S. Buzdar A. Smith T. Kau S. Yang Y. Hortobagyi G. (2004) Is breast cancer survival improving? Cancer 100: 44–52.
36. Gonzales-Angulo A. Litto J. Broglio K. Meric-Bernstam F. Rakkhit R. Cardoso F. et al. (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27: 5700–5706.
37. Gradishar W. (2013) Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol doi: 10.1093/annonc/mdt217.
38. Gradishar W. Tjulandin S. Davidson N. Shaw H. Desai N. Bhar P. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794–7803.
39. Harvey V. Mouridsen H. Semiglazov V. Jakobsen E. Voznyi E. Robinson B. et al. (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24: 4963–4970.
40. Hayashi M. Okumura Y. Osako T. Toyozumi Y. Arima N. Iwase H. et al. (2011) Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. Int J Clin Oncol 16: 694–700.
41. Henderson I. Allegra J. Woodcock T. Wolff S. Bryan S. Cartwright K. et al. (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571.
42. Hortobagyi G. Gomez H. Li R. Chung H. Fein L. Chan V. et al. (2010) Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 122: 409–418.
43. Icli F. Akbulut H. Uner A. Yalcin B. Baltali E. Altinbas M. et al. (2005) Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group Br J Cancer 92: 639–644.
44. Joensuu H. Holli K. Heikkinen M. Suonio E. Aro A. Hietanen P. et al. (1998) Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16: 3720–3730.
45. Jones S. (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8: 224–233.
46. Jones S. Erban J. Overmoyer B. Budd G. Hutchins L. Lower E. et al. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542–5551.
47. Jones S. Winer E. Vogel C. Laufman L. Hutchins L. O'Rourke M. et al. (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567–2574.
48. Keller A. Mennel R. Georgoulias V. Nabholtz J. Erazo A. Lluch A. et al. (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22: 3893–3901.
49. Konecny G.E. Pegram M.D. Venkatesan N. Finn R. Yang G. Rahmeh M. et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 (3): 1630–1639.
50. Mannocci A. de Feo E. de Waure C. Specchia M. Gualano M. Barone C. et al. (2010) Use of trastuzumab in HER2-positive metastatic breast cancer beyond progression: a systematic review of published studies. Tumori 96: 385–391.
51. Martín M. Ruiz A. Muñoz M. Balil A. García-Mata J. Calvo L. et al. (2007) A Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8: 219–225.
52. Mauri D. Polyzos N.P. Salanti G. Pavlidis N. Ioannidis J. (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100: 1780–1791.
53. Metro G. Giannarelli D. Gemma D. Lanzetta G. Ciccarese M. Papaldo P. et al. (2010) Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Breast J 16: 66–72.
54. Miller K. Chap L. Holmes F. Cobleigh M. Marcom P. Fehrenbacher L. et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799.
55. Nabholtz J. Senn H. Bezwoda W. Melnychuk D. Deschênes L. Douma J. et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413–1424.
56. Norris B. Pritchard K. James K. Myles J. Bennett K. Marlin S. et al. (2000) Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic / recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385–2394.
57. O'Regan R. Ozguroglu M. Andre F. Toi M. Jerusalem G. Wilks S. et al. (2013) Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 31(Suppl.): abstract 505.
58. O'Shaughnessy J. (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10: 20–29.
59. O'Shaughnessy J. Miles D. Vukelja S. Moiseyenko V. Ayoub J. Cervantes G. et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823.
60. Pagani O. Senkus E. Wood W. Colleoni M. Cufer T. Kyriakides S. et al. (2010) International guidelines foe management of metastatic breast cancer: Can metastatic breast cancer be cured? J Natl Cancer Inst 102: 456–463.
61. Palumbo R. Bernardo A. Riccardi A. Sottotetti F. Teragni C. Bernardo G. (2012) Multiple chemotherapy lines in metastatic breast cancer: Which survival benefit for women with hormone receptor-positive disease? J Clin Oncol 30(Suppl.): abstract 589.
62. Pegram M. Liao J. (2012) Trastuzumab treatment in multiple lines: current data and future directions. Clin Breast Cancer 12: 10–18.
63. Planchat E. Abrial C. Thivat E. Mouret-Reynier M. Kwiatkiwski F. Pomel C. et al. (2011) Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast 20: 574–578.
64. Porkka K. Blomqvist C. Rissanen P. Elomaa I. Pyrhönen S. (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12: 1639–1647.
65. Portera C. Walshe J. Rosing D. Denduluri N. Berman A. Vatas U. et al. (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14: 2710–2716.
66. Roché H. Vahdat L. (2011) Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 22: 1000–1010.
67. Saad E. Katz A. Buyse M. (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 28: 1958–1962.
68. Sjöström J. Blomqvist C. Mouridsen H. Pluzanska A. Ottosson-Lönn S. Bengtsson N. et al. (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194–1201.
69. Slamon D. Clark J. Wong S. Levin W. Ullrich A. McGuire W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177–182.
70. Slamon D. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bayamonde A. et al (2001) Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
71. Sparano J. Vrdoljak E. Rixe O. Xu B. Manikhas A. Medina C. et al. (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28: 3256–3263.
72. Stemmler H. Kahlert S. Siekiera W. Untch M. Heinrich B. Heinemann V. (2005) Prolonged survival of patients receiving trastuzumab beyond disease progression for HER 2 overexpressing metastatic breast cancer (MBC). Onkologie 28: 582–586.
73. Swain S. Kim S. Cortés J. Ro J. Semiglazov V. Campone M. et al. (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471.
74. Tacca O. LeHeurteur M. Durando X. Mouret-Reynier M. Abrial C. Thivat E. et al. (2009) Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest 27: 81–85.
75. Theriault R. Carlson R. Allred C. Anderson B. Burstein H. Edge S. et al. (2013) Breast Cancer, Version 3.2013. J Natl Compr Cancer Network 11: 753–761
76. Thomas E. Gomez H. Li R. Chung H. Fein L. Chan V. et al. (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25: 5210–5217.
77. Vauléon E. Mesbah H. Laguerre B. Gédouin D. Lefeuvre-Plesse C. Levêque J. et al. (2010) Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge. Cancer Chemother Pharmacol 66: 113–120.
78. Verma S. Miles D. Gianni L. Krop I. Welslau M. Baselga J. et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–1791.
79. von Minckwitz G. Du Bois A. Schmidt M. Maass N. Cufer T. de Jongh F. et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27: 1999–2006.
80. von Minckwitz G. Schwedler K. Schmidt Maass N. Barinoff J. Mundhenke C. et al. (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 47: 2273–2281.
81. Waddell T. Kotsori A. Constantinidou A. Yousaf N. Ashley S. Parton M. et al. (2011) Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. Br J Cancer 104: 1675–1679.